Abstract
A recent pre-clinical study has shown that brain-penetrating statins can reduce risks of relapse to cocaine and nicotine addiction in rats. Based on this information, we conducted a randomized, double-blind, placebo-controlled, proof-of-concept trial to assess the efficacy of simvastatin in smoking cessation. After informed consent, 118 participants received behavioral cessation support and were randomly assigned to a 3-month treatment with simvastatin or placebo. The primary outcome was biochemically verified abstinence or smoking reduction at 3-month post-target quit date (TQD). Secondary outcomes were abstinence during weeks 9-12 post-TQD, prolonged abstinence or reduction at months 6 and 12 post-TQD, safety and craving assessed at each visit during the 3-month period of treatment. Simvastatin treatment was not associated with higher 3-month abstinence or smoking reduction compared to placebo. There was no significant difference in any of the secondary outcomes. Simvastatin was well tolerated. Over 3 and 9 months follow-up period, 78% simvastatin and 69% placebo participants were retained in the study. At 6 and 12 months, smoking remained significantly reduced from baseline in both groups. Our results demonstrate that a 3-mo...Continue Reading
References
Sep 1, 1991·British Journal of Addiction·T F HeathertonK O Fagerström
Feb 1, 1994·Pharmaceutical Research·A SahekiA Tsuji
Aug 1, 1993·Addiction·R L RichmondI W Webster
Apr 13, 2000·Archives of Internal Medicine·K WilsonD Cook
Jul 3, 2003·JAMA : the Journal of the American Medical Association·Julia A Critchley, Simon Capewell
May 2, 2009·Néphrologie & thérapeutique·UNKNOWN Groupe de travail de la Société de Néphrologie
Jul 9, 2009·Drugs·Carlos Jiménez-RuizThomas Hering
Mar 26, 2010·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Ivan BerlinStephen J Heishman
Nov 26, 2010·Journal of Alzheimer's Disease : JAD·Saleta SierraJavier S Burgos
Mar 29, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Leigh V PanlilioSteven R Goldberg
Jan 4, 2013·Parkinsonism & Related Disorders·François TisonErwan Bezard
Mar 16, 2013·British Journal of Clinical Pharmacology·Henri-Jean AubinIvan Berlin
Jan 9, 2014·JAMA : the Journal of the American Medical Association·Kate CahillTim Lancaster
Oct 16, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Claudia ChauvetMarcello Solinas
Mar 26, 2016·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Kenneth A PerkinsEric C Donny
Apr 26, 2016·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Melanie L SchwandtMarkus Heilig
May 24, 2016·Clinical Pharmacology and Therapeutics·M E MooneyD K Hatsukami
Jun 30, 2016·BMJ : British Medical Journal·Anthony MatthewsKrishnan Bhaskaran
Sep 13, 2016·Lancet·Rory CollinsRichard Peto
Oct 14, 2016·Lancet·UNKNOWN GBD 2015 Risk Factors Collaborators
Nov 25, 2016·BMC Public Health·Lutz SiemerRobbert Sanderman
Jan 6, 2017·MMWR. Morbidity and Mortality Weekly Report·Stephen BabbAhmed Jamal
Sep 25, 2017·Alcoholism, Clinical and Experimental Research·Matthew B PomrenzeRobert O Messing